Compare Capri Holdings Ltd (CPRI) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Capri Holdings Ltd vs Incyte Corporation — how do they compare? Capri Holdings Ltd trades at $15.46 (market cap $1.77B), while Incyte Corporation trades at $120.77 (market cap $24.48B). The key difference: Incyte Corporation is far larger — about 13.8× Capri Holdings Ltd's market cap, and Incyte Corporation is trading nearer its 52-week high, Capri Holdings Ltd nearer its low. Which is the better fit depends on your goals.
| CPRI | INCY | |
|---|---|---|
Market Cap | $1.77B | $24.48B |
Sector | Consumer Staples | Health |
52-Week High | $27.66 | $129.93 |
52-Week Low | $14.98 | $81.66 |
Enterprise Value | $3.05B | $19.98B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Capri Holdings (CPRI) trades at $15.66, down 65% over five years and near 52-week lows after recent analyst downgrades. The stock shows bearish technical signals with neutral oscillators but faces fundamental challenges including declining revenue from $5.7B in 2022 to $4.4B in 2025 and a net loss of $1.18B last year. Recent Q1 2027 earnings beat expectations with $0.67 EPS versus $0.41 expected, driven by margin improvements and Jimmy Choo growth, though management cut full-year revenue guidance citing Michael Kors weakness.
The investment case hinges on successful execution of the post-Versace turnaround strategy, with the stock trading below consensus price targets offering potential upside if Michael Kors stabilizes. However, significant risks remain including ongoing revenue declines, luxury market softness, and high debt levels requiring careful monitoring of quarterly execution against revised guidance.
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Capri Holdings Ltd
Michael Kors, Versace, and Jimmy Choo are the brands of Capri Holdings, a marketer, distributor, and retailer of upscale accessories and apparel. Kors, Capri's largest brand, offers handbags, footwear, and apparel through more than 800 company-owned stores, wholesale, and e-commerce. Versace (acquired in 2018) is known for its ready-to-wear luxury fashion, while Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. John Idol has served as CEO since 2003.
Read more on CPRI →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
